Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share purchase price of 1751.4347 pence per share.
Material Changes
The filing details an increase in the holding of Ordinary Shares by a connected person, Dr. S. Dexter, following the re-investment of a dividend paid on July 11, 2013. This transaction involved the purchase of 126 shares on April 12, 2013.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a specific share transaction.
Key Facts for Investor Verification
- Transaction Type: Increase in shareholding by a connected person (Dr. S. Dexter) via dividend re-investment.
- Shares Acquired: 126 Ordinary Shares.
- Purchase Price: 1751.4347 pence per share.
- Transaction Date: April 12, 2013.
- Notification Date: July 18, 2013.
- Dividend Date: July 11, 2013.